Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Other Non-Current Liabilities (2021 - 2025)

Historic Other Non-Current Liabilities for SAB Biotherapeutics (SABS) over the last 5 years, with Q3 2025 value amounting to $2.4 million.

  • SAB Biotherapeutics' Other Non-Current Liabilities fell 4166.66% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 4166.66%. This contributed to the annual value of $6.4 million for FY2024, which is 4573.55% down from last year.
  • SAB Biotherapeutics' Other Non-Current Liabilities amounted to $2.4 million in Q3 2025, which was down 4166.66% from $2.0 million recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Other Non-Current Liabilities high stood at $11.8 million for Q4 2023, and its period low was $238344.0 during Q1 2023.
  • In the last 5 years, SAB Biotherapeutics' Other Non-Current Liabilities had a median value of $2.9 million in 2022 and averaged $3.7 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Other Non-Current Liabilities tumbled by 9700.63% in 2022, and later surged by 356878.6% in 2023.
  • Over the past 5 years, SAB Biotherapeutics' Other Non-Current Liabilities (Quarter) stood at $10.7 million in 2021, then plummeted by 97.01% to $320930.0 in 2022, then surged by 3568.79% to $11.8 million in 2023, then crashed by 45.74% to $6.4 million in 2024, then plummeted by 62.72% to $2.4 million in 2025.
  • Its last three reported values are $2.4 million in Q3 2025, $2.0 million for Q2 2025, and $1.4 million during Q1 2025.